PURPLE BIOTECH LTD. - AMERICAN DEPOSITARY SHARES

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

25 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024

28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

14 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

05 Mar 2024 07:55:55 By Nasdaq GlobeNewswire

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

13 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

01 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

20 Dec 2023 08:05:00 By Nasdaq GlobeNewswire

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

14 Dec 2023 06:50:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Third Quarter 2023 Financial Results

21 Nov 2023 06:50:17 By Nasdaq GlobeNewswire

Purple Biotech Fortifies NT219 Patent Protection

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

19 Oct 2023 15:55:53 By Nasdaq GlobeNewswire

Purple Biotech Announces $5 Million Registered Direct Offering

17 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

06 Oct 2023 07:50:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

03 Oct 2023 07:50:00 By Nasdaq GlobeNewswire

Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023

21 Sep 2023 08:00:01 By Nasdaq GlobeNewswire

Purple Biotech Reports Second Quarter 2023 Financial Results

22 Aug 2023 09:29:00 By Nasdaq GlobeNewswire

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

11 Jul 2023 08:15:00 By Nasdaq GlobeNewswire

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

16 May 2023 16:00:02 By Nasdaq GlobeNewswire

Purple Biotech Debuts Scientific Advisory Board

25 Apr 2023 08:00:02 By Nasdaq GlobeNewswire